Incorporating New Medications into Acne Treatment

As an introduction to a panel discussion on incorporating new medications into acne treatment, dermatology experts provide an overview of the who, what, and when of acne.

Julie C. Harper, MD, comments on the prevalence of acne in women and highlights differences from men.

Dermatologists discuss the impact of acne vulgaris on the quality of life experienced by their patients.

James Q. Del Rosso, DO, comments on the facts and myths surrounding contributory and predisposing factors that influence the development of acne.

Dermatology experts comment on the clinical manifestation of acne and the importance of differential diagnosis.

An overview of common sequelae and potential complications of acne, including physiological and psychological scaring.

Key opinion leaders in dermatology discuss approaches to selecting treatment based on the pathophysiology of acne.

Dermatology experts comment on the safety and efficacy of the newly approved topical therapies clascoterone cream 1% and micronized tretinoin 0.05% lotion.

A panel of dermatology experts reviews the safety and efficacy data of the newly approved topical therapies trifarotene 0.005% cream, tazarotene 0.045% lotion, and minocycline 4% foam.

During an informative discussion on current treatment options in acne, dermatology experts address the newly approved oral therapies sarecycline and micronized isotretinoin.

Key opinion leaders in dermatology share thoughts on unmet needs and the future direction of acne care.